Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 180

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype

Open access
Della Corte, Carminia M., Sen, Triparna, Gay, Carl M., Ramkumar, Kavya, Diao, Lixia, Cardnell, Robert J., Rodriguez, Bertha Leticia, Stewart, C. Allison, Papadimitrakopoulou, Vassiliki A., Gibson, Laura, Fradette, Jared J., Wang, Qi, Fan, Youhong, Peng, David H., Negrao, Marcelo V., Wistuba, Ignacio I., Fujimoto, Junya, Solis Soto, Luisa M., Behrens, Carmen, Skoulidis, Ferdinandos, Heymach, John V., Wang, Jing, Gibbons, Don L., Byers, Lauren A. · 2020 · Journal of Thoracic Oncology

Abstract

Purpose Although the combination of anti-PD1/PD-L1 with platinum chemotherapy is a standard of care for NSCLC, clinical responses vary. While predictive biomarkers are validated for immunotherapy, including PD-L1 expression, tumor mutational burden, and inflamed immune microenvironment, their relevance to chemo-immunotherapy combinations is less clear. We have recently shown that activation of the STING innate immune pathway enhances immunotherapy response in SCLC. We hypothesize that STING pathway activation may predict and underlie predictive correlates of anti-tumor immunity in NSCLC. Experimental Design We analyzed transcriptomic and proteomic profiles in two NSCLC cohorts from our institution (treatment-naïve-PROSPECT; relapsed-BATTLE-2) and The Cancer Genome Atlas (total n=1320). Tumors were stratified by STING activation based on protein and/or mRNA expression of cGAS, phospho-STING, and STING-mediated-chemokines CCL5 and CXCL10. STING activation in patient tumors and in platinum-treated preclinical NSCLC models was correlated with biomarkers of immunotherapy response. Results STING activation is associated with higher levels of intrinsic DNA damage, targetable immune checkpoints, and chemokines in treatment-naïve and relapsed lung adenocarcinoma. We observed that tumors with lower STING and immune gene expression show higher frequency of STK11 mutations; however, we identified a subset of these tumors that are TP53 co-mutated and display high immune- and STING- related gene expression. Treatment with cisplatin increases STING pathway activation and PD-L1 expression in multiple NSCLC preclinical models, including adeno- and squamous cell carcinoma. Conclusions STING pathway activation in NSCLC predicts features of immunotherapy response and is enhanced by cisplatin treatment, suggesting a possible predictive biomarker, and mechanism, for improved response to chemo-immunotherapy combinations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2020.01.009

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 180

Metadata

Authors
Della Corte, C. M., Sen, T., Gay, C. M., Ramkumar, K., Diao, L., Cardnell, R. J., Rodriguez, B. L., Stewart, C. A., Papadimitrakopoulou, V. A., Gibson, L., Fradette, J. J., Wang, Q., Fan, Y., Peng, D. H., Negrao, M. V., Wistuba, I. I., Fujimoto, J., Solis Soto, L. M., Behrens, C., Skoulidis, F., Heymach, J. V., Wang, J., Gibbons, D. L., & Byers, L. A.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2020-05
Volume
15
Issue
5
Pages
777-791
ISSN
1556-0864 (ISSN-L)
OpenAlex
W3006378317
Cited by
180
References
15
FWCI
9.94
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype. https://app.cochat.ai/papers/10.1016/j.jtho.2020.01.009
The paper
Della Corte, C. M., Sen, T., Gay, C. M., Ramkumar, K., Diao, L., Cardnell, R. J., Rodriguez, B. L., Stewart, C. A., Papadimitrakopoulou, V. A., Gibson, L., Fradette, J. J., Wang, Q., Fan, Y., Peng, D. H., Negrao, M. V., Wistuba, I. I., Fujimoto, J., Solis Soto, L. M., Behrens, C., . . . Byers, L. A. (2020). STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2020.01.009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.